The predictive biomarkers of cancer immunotherapy mainly include PD-L1 expression, immune cell infiltration, tumor mutational burden, specific gene mutations, and so on (Chen et al., 2018; Darvin et al., 2018; Yi et al., 2018; Otoshi et al., 2019). This evidence concerns the gene CD274 and neoplasm.